|  |  |  |
| --- | --- | --- |
| TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTERSCHOOL OF MEDICINEPSYCHIATRY DEPARTMENTPOLICY AND PROCEDURE | REVIEW NO:2 | NUMBER:N 4 |
| PREPARED BY: APPROVED BY:KARY BLAIR TERRY MCMAHON, MD | ORIGINAL APPROVAL DATE:APRIL 2004 | MOST RECENT REVIEW APPROVAL DATE:DECEMBER 4, 2018 |
| TITLE:Observation Following Injection | PAGE:1 of 1 |
| 1. **GENERAL STATEMENT OF POLICY:**

Statement of Purpose: Patients will be observed following receipt of an injectable medication.1. **SCOPE:**

This policy covers Psychiatry1. **ADMINISTRATION:**

-Prior to administration of injection, patient will be asked two patient identifiers (e.g. name, date of birth). - The patient’s blood pressure and pulse will be checked prior to injection. If a patient’s vital signs are not WNL, the physician will be consulted before proceeding with the injection.-After a patient receives an injection the nurse will observe the patient in the clinic for a minimum of fifteen minutes. The patient’s blood pressure and pulse will be taken following the observation period. If vital signs are not WNL or if an adverse reaction is observed, the provider will be consulted for any additional action.All information pertaining to the injection will be documented in the patient’s EMR and sent to the provider for signature.-Injectable medications administered in the clinic include Haldol Decanoate; Risperdal Consta; invega Sustenna; and Abilify Maintena. Injectable Diphenhydramine 25mg is available for administration with physician orders, PRN1. **DISTRIBUTION:**

This policy shall be distributed to Psychiatry.  |